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Abstract
Background: Assessment of quality of care using classical threshold measures (TM) is open to debate. Measures
that take into account the clinician’s actions and the longitudinal nature of chronic care are more reliable, although
their major limitation is that they require more sophisticated electronic health records. We created a clinical action
measure (CAM) for the control of LDL and non-HDL cholesterol from low-complexity data, and investigated how
quality of care in individual diabetes centres based on the CAM is related to that based on the classical TM.
Methods: Data was used from 3421 diabetes patients treated in 95 centres, collected in two consecutive retrospective
data collections. Patients met the TM when their index value was below target. Patients met the CAM when their index
value was below target or above target but for whom treatment initiation or intensification, or possible contraindication,
was indicated.
Results: Based on the TM, 60–70 % of the patients received good care. This percentage increased significantly using the
CAM (+5 %, p < 0.001). At the centre level, the CAM was associated with a higher median score, and a change in
position among centres (‘poor’, ‘good’ or ‘excellent’ performer) for 5–10 % of the centres.
Conclusions: Judging quality of diabetes care of a centre based on a TM may be misleading. Low-complexity
data available from a quality improvement initiative can be used to construct a more fair and feasible measure of
quality of care.
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Background
Since the mid-nineties, several national and international
initiatives have been created in order to assess quality of
diabetes care [1]. Although they generally use a common
set of quality indicators, the purposes of these initiatives
differ. Internal quality assessment projects aim to im-
prove quality of care, whereas national efforts rather as-
sess public accountability. Another objective of these
initiatives is research where they are used to evaluate
programs and assess the effect of policy changes on
healthcare quality [2, 3].
Clinical guidelines and indicator selection consider-
ations have led to the development of quality indica-
tors as we know them so far [3, 4]: dichotomous
quality indicators covering care processes (such as foot
and eye examinations), intermediate outcomes which
are immediately influenced by clinical interventions
and are predictive for downstream outcomes (such as
glycated haemoglobin (HbA1c), low-density lipopro-
tein (LDL) cholesterol, blood pressure), and end-point
outcomes (such as blindness, amputation, cardiovascu-
lar complications).
However, cross-sectional threshold measures (TM)
based on intermediate outcomes have several limitations
and their fairness to assess quality of care is under de-
bate [2, 5–7]. First, there seems to be no single target for
all, and the use of more individualized targets based on
patient characteristics is increasingly advocated [8, 9].
Secondly, the absolute risk reduction is not a stepwise
process, but continuous (and can even be log-linear).
Therefore, as a patient approaches the threshold, the
marginal benefit of increased treatment decreases while
the likelihood of treatment-related side effects and costs
increases [2, 6]. Last but not least, all laboratory tests
have intrinsic variation [2].
Increasing efforts aim to refine the current quality in-
dicators and develop other types of measures, for in-
stance by extending the TM with patient characteristics
and appropriateness of care [2, 6]. One of those new
measures is the clinical action measure (CAM). A CAM
defines good quality of care not exclusively by a good
intermediate outcome, but also by evidence of an appro-
priate clinical action upon poor control. In addition, by
evaluating quality of care within a certain measurement
period, it takes into account the longitudinal nature of
chronic patient care [10].
The major limitation, however, of constructing more
complex quality of care measures such as a CAM is that
it requires more structured and sophisticated electronic
health records containing explicit data elements reflect-
ing provider actions (such as dates and levels of tests,
medication doses) as well as implicit data elements
reflecting patient behavior, comorbidity, medication
safety and cost concerns [6].
Although these high-complexity data elements are be-
coming increasingly available, they remain restricted to
experimental investigations of new quality indicators
and have rarely been applied to large, nationwide initia-
tives of quality measurement. Therefore, the general
framework of this study was to investigate whether more
sophisticated indicators, such as a CAM, can be con-
structed from existing but rather low-complexity data
collected cross-sectionally, and how this affects the mes-
sage to clinicians receiving feedback on the scores.
The specific aims of this study were to investigate (a)
whether a CAM can be created for the control of the
intermediate LDL and non-high-density lipoprotein
(non-HDL) cholesterol using the set of data elements
available from a large cross-sectional study; (b) how
quality of care defined by the CAM is related to quality
of care defined by the classical TM; (c) whether this new
measure can be used to give more reliable feedback to
the centres in order to improve their quality of care; and
(d) whether this principle of measuring quality of care
can be generalized for the control of blood pressure.
Data were used from the Initiative for Quality improve-
ment and Epidemiology in patients with Diabetes (IQED),
a nationwide quality improvement initiative among
insulin-treated diabetic patients attending hospital-based
specialist diabetes centres in Belgium [11].
Methods
Study population and cohort construction
Data was used from the IQED data collections in 2009
and 2011. The IQED study population is limited to adult
(aged ≥18 years) patients with type 1 or type 2 diabetes,
treated with at least two insulin injections per day. The
IQED data collections took place within a 2 month
period. Each centre was asked to complete a standard-
ized electronic questionnaire with the patient’s most re-
cent data by reviewing charts of a 10 % sample of their
patients. Patient sampling, based on the last name start-
ing from a random letter, was determined at a national
level in the most recent alphabetical patient list until the
required number of consecutive patients was reached.
The questionnaire contained information on performed
processes, intermediate outcomes and complications.
The collected data were used to create a nationwide re-
port and provide centres with individual feedback (in
which they were compared anonymously to other par-
ticipating centres, called benchmarking feedback) in
order to improve their centre-specific quality of care.
The IQED project is managed by our institute. Use of
these data has been approved by the Belgian privacy
commission (no. 13/092). Details of this quality im-
provement initiative as well as details of the question-
naire have been published [11] and are available from
author by request.
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In this study, only patients registered in both 2009 and
2011 were used (n = 3808). Data from two consecutive
cross-sectional data collections were combined to create
one measurement period from 2009 to 2011. The meas-
urement period was defined as the period between the
last day of the first of the two consecutive data collec-
tions and the last day of the second data collection, and
totalled 27 months. Compared to the total IQED popula-
tion in 2011, these 3808 patients were more often pa-
tients with type 1 diabetes (35.3 % vs. 29.5 % of the total
IQED population, p < 0.001). In general, the selected
type 1 diabetes patients were younger (49 vs. 62 years
old, p < 0.001) and had a longer diabetes duration (21 vs.
17 years old, p < 0.001), whereas the selected type 2 dia-
betes patients were older (70 vs. 62 years old, p < 0.001),
had a slightly longer diabetes duration (18 vs. 17 years
old, p < 0.01) and were more often female (52 vs. 49 %,
p < 0.05) compared to the total IQED population.
Study cohorts were constructed to develop measures
for the control of lipids (based on LDL cholesterol and
non-HDL cholesterol), and blood pressure. Patients
without, for their registration in 2011, an LDL choles-
terol value (or a non-HDL cholesterol value for the mea-
sures based on non-HDL cholesterol, see below), a
known status (presence or absence) of cardiovascular
(CV) history (defined as a history of myocardial infarc-
tion (MI), cerebral vascular accident (CVA), percutan-
eous coronary intervention (PCI), coronary artery bypass
graft (CABG) or transient ischemic attack (TIA)), or a
known status (presence or absence) of end-stage kidney
disease (defined as a history of kidney transplantation,
peritoneal dialysis or haemodialysis) were excluded. Pa-
tients without a known lipid-lowering treatment status
(treated or not treated, for both statins and fibrates) for
their registration in 2009 and in 2011, were also ex-
cluded. This resulted in a final LDL cholesterol cohort
of 1673 patients and a final non-HDL cholesterol cohort
of 3421 patients. Excluded patients of both cohorts did
not differ from the final sample in a clinically meaning-
ful way in terms of age, sex, and diabetes duration.
The index value was defined as the most recent value
within the measurement period, i.e. the value recorded
for the data collection in 2011. The LDL cholesterol
value was calculated by the Friedewald formula [12] for
patients with a triglyceride value <400 mg/dl and for
whom lipids were measured on a fasted blood sample.
As the number of patients for whom an LDL choles-
terol index value could be calculated strongly decreased
when requiring a fasted sample and triglyceride value
<400 mg/dl, we used non-HDL cholesterol as an alter-
native [13]. The non-HDL cholesterol value was calcu-
lated by subtracting the HDL cholesterol value from
the total cholesterol value. The target values for non-
HDL cholesterol were 30 mg/dl higher compared to the
target values for LDL cholesterol.
Details about the construction of the cohort and de-
velopment of the measures based on blood pressure can
be found in Additional file 1.
Measure development
We evaluated two quality measures: (1) the TM, and (2)
the CAM. The criteria for meeting the TM and the
CAM are shown in Fig. 1a and b, respectively. Creating
the TM requires the presence of an LDL or non-HDL
cholesterol index value, whereas the CAM requires, in
addition, a known lipid-lowering treatment status and a
a b
Fig. 1 Flowchart describing the construction of the threshold measure and clinical action measure. Flowchart used to determine whether a
patient met the threshold measure (Fig. 1a) or the clinical action measure (Fig. 1b)
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known contraindication status. The LDL and non-HDL
cholesterol index values were used as starting point.
Threshold measure (TM)
Patients were defined as receiving good quality of care
when a target value was reached. Based on the guide-
lines used at the time of the study [13–15], <100 mg/dl
was used as target value for LDL cholesterol (<70 mg/dl
for those with CV history), and <130 mg/dl for non-
HDL cholesterol (<100 mg/dl for those with CV
history).
Clinical action measure (CAM)
Patients were defined as receiving good quality of care
when the target value was reached or when an appropri-
ate clinical action (treatment initiation or intensification)
was taken between 2009 and 2011. If there was no treat-
ment initiation or intensification recorded, patients also
met the measure when a contraindication was recorded.
The same target values were used as for the TM.
Treatment initiation or intensification was investigated
by comparing the treatment regimen recorded in 2009
to the treatment regimen recorded in 2011. In the IQED
questionnaire, centres could indicate whether the patient
was treated (=1) or not (=0) with statins or fibrates, re-
spectively. Patients were considered non-treated when
treatment with neither statins nor fibrates was recorded
(statins = 0 & fibrates = 0). As ezetimibe was only a part
of the questionnaire from the data collection in 2011,
this class of lipid-lowering drugs was not taken into ac-
count in this study.
As we did not have information on drug dose, treat-
ment intensification was defined as the addition of an
extra class of lipid-lowering drugs to the existing treat-
ment regimen. A switch from one drug class to another
was not considered as intensification, although it might
be an appropriate action upon an indicated side effect,
or lack of therapeutic effect.
Treatment initiation was defined as going from no
treatment in 2009 to any treatment in 2011.
End-stage kidney disease, defined as the presence of
kidney transplantation, peritoneal dialysis or haemodi-
alysis, was used as a possible contraindication for treat-
ment intensification or initiation.
Statistical analysis
Patient characteristics were summarized as means (95 %
confidence interval (CI)) or as frequencies (percentage).
Missingness of data elements was investigated. The evo-
lution of the proportion of patients treated was investi-
gated between the 2009 and 2011 data collections. The
total number of patients meeting the TM and the CAM
were determined, as well as the number of patients per
individual measure criterion. The centre-specific score
for each measure was calculated. Funnel plots were used
to detect statistical outliers: centres with a score of 2 (or
3) standard deviations (SD) above or below the overall
score [16]. We categorized centres in three ranges: the
normal range (within 2 SDs around the overall score),
the high-outlier range (>2 SDs above the overall score)
and the low-outlier range (>2 SDs below the overall
score). Finally, characteristics of patients meeting the
measure were compared with those of patients not
meeting the measure. Most analyses were stratified by
diabetes type. The t-test was used to compare continu-
ous variables. The χ2-test was used to compare categor-
ical variables. The Wilcoxon-test was used to compare
the medians of the distributions of centre-specific indi-
cator scores. Statistical significance was defined as p-
value <0.05. All analyses were done in R, version 2.15.2.
Results
Study cohort and patient characteristics
Two consecutive data collections were used to construct
a cohort followed in a measurement period from 2009
to 2011. Patient characteristics of the non-HDL choles-
terol cohort at the end of the measurement period are
summarized in Table 1. The characteristics of patients
for whom an LDL cholesterol index value could be cal-
culated did not significantly differ from patients for
whom it could not.
Creating the measure: availability and evolution of
required data elements
We first investigated the proportion of patients regis-
tered in both data collections for whom the separate re-
quired data elements were recorded (Additional file 2).
An LDL cholesterol index value could be calculated for
70–75 % of the patients. This percentage was reduced to
44–47 % when taking into account the requirement of a
fasted blood sample and a triglyceride value <400 mg/dl
(data not shown). A non–HDL cholesterol index value
could be calculated for 95–96 % of the patients. The
lipid-lowering treatment status, contraindications status
and CV history were completed for >95 % of the study
population. Completeness of the required data elements
of patients registered in both 2009 and 2011 did not dif-
fer from the completeness of the required data elements
in the total IQED population.
Next, we investigated in detail the treatment status
over time in our final study cohorts (Additional file 3).
In general, the greatest proportion of patients treated
with either statins or fibrates were patients with type 2
diabetes. The proportion of patients treated at the end
of the measurement period was consistently and signifi-
cantly higher compared to the start of the measurement
period indicating that overall, additional patients started
treatment within the given period. For the LDL
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cholesterol cohort, this percentage increased from
37.9 % type 1 diabetes patients in 2009 to 46.8 % in 2011
(p < 0.001) and from 74.5 % type 2 diabetes patients in
2009 to 80.3 % in 2011 (p < 0.001) in the LDL cholesterol
cohort. These evolutions were similar in the non-HDL
cholesterol cohort and confirmed in the total IQED
population (data not shown).
Finally, we investigated treatment initiation and in-
tensification at the individual patient level. In the LDL
cholesterol cohort, 71 of the 568 type 1 diabetes patients
(12.5 %) started treatment and two patients (0.3 %) in-
tensified their treatment between 2009 and 2011. Of the
1105 type 2 diabetes patients, 109 patients (9.9 %)
started treatment and 21 patients (1.9 %) intensified
their treatment. These proportions were similar in the
non-HDL cholesterol cohort.
Meeting the measure: TM vs. CAM
The criteria for meeting the TM and CAM are shown in
Fig. 1. Target values were adjusted for the presence or
absence of CV history.
60.2 % of the type 1 diabetes patients and 63.0 % of
the type 2 diabetes patients met the TM based on LDL
cholesterol (Table 2). Patients without CV history were
significantly more likely to meet their target value com-
pared to those with CV history (62.8 % vs. 31.9 % of the
type 1, p < 0.05, and 72.9 % vs. 39.5 % of the type 2 dia-
betes patients, p < 0.001). Looking at the TM based on
non-HDL cholesterol, 70.5 % of the type 1 diabetes
patients and 61.7 % of the type 2 diabetes patients met the
TM. Again more patients without CV history met their
target value compared to those with CV history (Table 2).
Meeting the CAM is the result of an index value below
target, or an index value above target but with an indi-
cated treatment initiation or intensification. Table 2
shows that among type 1 diabetes patients with an LDL
cholesterol index value above target, three patients with
and 23 without CV history had treatment initiation or
intensification during the measurement period. In
addition, four patients had a reported contraindication
to treatment initiation or intensification. As a result, the
proportion of patients meeting the measure significantly
increased from 60.2 % based on the TM to 65.5 % based
on the CAM (p < 0.001). Similarly, among type 2 diabetes
patients with an LDL cholesterol index value above target,
27 patients with and 26 without CV history had treatment
initiation or intensification during the measurement period.
In addition, nine patients had a reported contraindication
Table 1 Patient characteristics
Measurement period 2009–2011
Months 27
Patients 3421
Patient characteristics
Diabetes type Type 1 Type 2
(value) (n) (value) (n)
Number of patients 1234 2187
Age (years), mean (95 % CI) 49 (48–50) 70 (69–70)
Diabetes duration (years), mean (95 % CI) 21 (20–22) −12 17 (17–18) −111
Male, % 60 48
Hba1c (%), mean (95 % CI) 7.9 (7.8–8.0) −2 7.5 (7.4–7.5) −13
Systolic blood pressure (mm Hg), mean (95 % CI) 128 (127–129) −8 135 (135–136) −20
Diastolic blood pressure (mm Hg), mean (95 % CI) 74 (74–75) −8 74 (74–75) −20
Total cholesterol (mg/dl), mean (95 % CI) 178.7 (176.8–180.6) 164.6 (163.1–166.1)
non-HDL cholesterol (mg/dl), mean (95 % CI) 114.2 (112.5–116.0) 114.2 (112.8–115.6)
LDL cholesterol (mg/dl), mean (95 % CI) 93.3 (91.7–94.8) −666 84.1 (82.9–85.3) −1082
CV-hist1, % 5.6 25.3 −4
CV-hist2, % 7.3 31.1
CV-hist3, % 9.6 −113 36.6 −157
Microvascular complication, % 54.1 −224 74.9 −333
Patient characteristics at the end of the measurement period of the type 1 diabetes and type 2 diabetes patients from the non-HDL cholesterol cohort. Values are
represented as means with their 95 % confidence interval (95 % CI), or as percentage (%). The negative values indicate the number of incomplete records that
were not taken into account for the calculation. CV-hist1 is defined as a history of MI, CABG or PCI. CV-hist2 is defined as a history of MI, CABG, PCI, TIA or CVA.
CV-hist3 is defined as a history of MI, CABG, PCI, TIA, CVA, peripheral bypass, or the absence of foot pulses. Microvascular complication is defined as any of the
following: albuminuria ≥30 mg/dl, creatinine ≥1.5 mg/dl, dialysis or kidney transplantation, retinopathy, neuropathy, and foot ulcer or amputation
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to treatment initiation or intensification. This lead to a sig-
nificant increase in the proportion of patients meeting the
measure: from 63.0 % based on the TM to 68.6 % based on
the CAM (p < 0.001).
A comparable increase was found for the measures
based on non-HDL cholesterol (Table 2).
Interestingly, the increase in proportion meeting the
measure from TM to CAM was higher among patients
Table 2 Number and percentage of patients meeting the threshold measure and the clinical action measure
Diabetes type Type 1 Type 2
(value) (n) (value) (n)
Threshold measure
Below target value
LDL index value
Total, patients (%) 342 (60.2) 568 696 (63.0) 1105
With CV history (LDL < 70 mg/dl), patients (%) 15 (31.9) 47 130 (39.5) 329
Without CV history (LDL < 100 mg/dl), patients (%) 327 (62.8) 521 566 (72.9) 776
non-HDL index value
Total, patients (%) 870 (70.5) 1234 1349 (61.7) 2187
With CV history (non-HDL < 100 mg/dl), patients (%) 46 (51.1) 90 285 (41.9) 680
Without CV history (non-HDL < 130 mg/dl), patients (%) 824 (72.0) 1144 1064 (70.6) 1507
Clinical action measure
Treatment and contraindication status
LDL index value
LDL ≥ 70 mg/dl, patients
Treatment initiation or intens. [init.] 3 [3] 27 [23]
Contraindication 2 4
LDL ≥ 100 mg/dl, patients
Treatment initiation or intens. [init.] 23 [22] 26 [23]
Contraindication 2 5
non-HDL index value
non-HDL≥ 100 mg/dl, patients
Treatment initiation or intens. [init.] 3 [3] 51 [36]
Contraindication 2 18
non-HDL≥ 130 mg/dl, patients
Treatment initiation or intens. [init.] 42 [40] 53 [46]
Contraindication 2 3
Total
LDL index value
Total, patients (%) 372 (65.5) ° 758 (68.6) °
With CV history, patients (%) 20 (42.5) $ 161 (48.9) °
Without CV history, patients (%) 352 (67.6) ° 597 (76.9) °
non-HDL index value
Total, patients (%) 919 (74.5) ° 1474 (67.4) °
With CV history, patients (%) 51 (56.7) ° 354 (52.1) °
Without CV history, patients (%) 868 (75.9) ° 1120 (74.3) °
The denominator is represented by (n). The target of the index value for patients with cardiovascular history (defined as the presence of a MI, CABG, PCI, TIA or
CVA) is lower than for those without cardiovascular history. Data are represented for the total number of type 1 or type 2 diabetes patients, as well as in the
absence or presence of cardiovascular history. The proportion with an index value equal to or above the threshold, but with a recorded treatment initiation or
intensification, or with a recorded contraindication for treatment intensification or initiation, is represented as number of patients. Statistical significance between
the percentage of patients meeting the threshold measure and the clinical action measure was tested by the χ2-test: p < 0.001 (°), p < 0.01 ($) and p < 0.05 (*) vs.
threshold measure
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with CV history (6–11 %) than among those without
(4–5 %).
Provider profiling according to the TM and the CAM
Table 3 summarizes the centre specific scores for the
two measures. Only centres with five or more patients in
the cohort were included. This led to a reduction from
95 centres that participated in IQED and had patients
registered in both 2009 and 2011, to 63 and 89 centres
for the measures based on LDL cholesterol and non-
HDL cholesterol respectively. The overall scores, using
the total number of patients as a denominator after ex-
cluding these centres, were not significantly different
from those in Table 2 (data not shown).
The median centre-specific score for the CAM was
significantly higher than for the TM: 68.8 % (CAM) vs.
63.6 % (TM) for the LDL cholesterol measures (p <
0.01), and 69.2 % (CAM) vs. 64.7 % (TM) for the non-
HDL cholesterol measures (p < 0.001). Between-centre
variability, as demonstrated by the range between the
10th and 90th percentile, was comparable for both the
TM and the CAM (Table 3).
Funnel plots were created to detect statistical outliers
(Fig. 2a-d). The funnel plot for the TM based on LDL
cholesterol shows two high outliers (centres 56 and 4),
and four low outliers (centres 49, 32, 36 and 50)
(Fig. 2a). The remaining 57 centres (90 %) were in the
normal range. The funnel plot for the CAM based on
LDL cholesterol shows that the overall score and the
centre-specific scores increased compared to the TM
(Fig. 2b). Three of the four original low outliers (centres
49, 32 and 36) moved to the normal range using the
CAM. One original high outlier (centre 4) moved to
the normal range. In addition, two new centres (centres
63 and 59) moved to the high-outlier range. In total, 59
centres (94 %) were within the normal range using the
CAM.
The funnel plot for the TM based on non-HDL chol-
esterol shows five high outliers (centres 66, 41, 6, 80
and 2), and five low outliers (centres 72, 3, 77, 31 and
73) (Fig. 2c). The remaining 79 centres (89 %) were in
the normal range. Again, the funnel plot for the CAM
based on non-HDL cholesterol shows that the overall
score and the centre-specific scores increased com-
pared to the TM (Fig. 2d). All original low outliers
remained identified as low outlier. Three original high
outliers (centres 66, 41 and 6) moved to the normal
range. One new centre (centre 25) moved from the
normal range to the high-outlier range. In total, 81
centres (91 %) were within the normal range using the
CAM.
Provider profiling applied to the control of blood
pressure
We applied the same principle to the control of blood
pressure, and investigated provider profiling. For these
analyses, only centres with five or more patients in the
cohort were included, leading to a total of 3609 patients
treated over 90 centres. Again the median centre-
specific score for the CAM was significantly higher than
for the TM: 40.7 % (CAM) vs. 30.2 % (TM, p < 0.001).
The funnel plots for the TM shows eight high outliers
(centres 62, 52, 87, 44, 81, 34, 10 and 64) and eight low
outliers (centres 40, 56, 78, 90, 80, 23, 36 and 57)
(Fig. 3a). The remaining 74 centres (82 %) were in the
normal range. The funnel plot for the CAM shows that
two original high outliers (centres 87 and 64) and five
original low outliers (centres 40, 56, 90, 23 and 57)
moved to the normal range (Fig. 3b). In addition, four
new centres (centres 69, 63, 22 and 6) moved to the
high-outlier range, and one centre (centre 43) moved to
the low-outlier range. In total, 75 centres (83 %) were
within normal range using the CAM.
Table 3 Overall mean percentage meeting the measure and
centre specific percentiles
Overall P10 P50 P90
Threshold measure
LDL index value
Number of centres 63
(Number of patients per centre, range) (5–99)
Total number of patients 1635
Total score (%) 61.7 48.4 63.6 76.4
non-HDL index
Number of centres 89
(Number of patients per centre, range) (5–126)
Total number of patients 3411
Total score (%) 64.8 49.6 64.7 77.1
Clinical action measure
LDL index value
Number of centres 63
(Number of patients per centre, range) (5–99)
Total number of patients 1635
Total score (%) 67.0 54.7 68.8 $ 81.0
non-HDL index value
Number of centres 89
(Number of patients per centre, range) (5–126)
Total number of patients 3411
Total score (%) 70.0 55.7 69.2 ° 80.6
Overall mean percentage meeting the measure for each measure, and the
centre specific 10th, 50th and 90th percentiles. Only centres with five or more
patients were taken into account. Statistical significance between median
centre specific score for the threshold measure and the clinical action measure
was tested by the Wilcoxon-test: p < 0.001 (°) and p < 0.01 ($) vs. the
threshold measure
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Characteristics of patients meeting the measure and of
those not meeting the measure
Table 4 shows the patient characteristics of those not
meeting a measure (TM-CAM-), not meeting the TM
but meeting the CAM (TM-CAM+), and meeting the
TM and CAM (TM+CAM+) based on LDL cholesterol
(Table 4a) and on non-HDL cholesterol (Table 4b).
Based on the measures with LDL cholesterol, diabetes
type was not associated with meeting the TM or CAM
(TM-CAM-: 34.5 % type 1 vs. 31.4 % type 2 diabetes pa-
tients, TM-CAM+: 5.3 % type 1 vs. 5.6 % type 2 diabetes
patients, TM+ CAM+: 60.2 % type 1 vs. 63.0 % type 2
diabetes patients). Based on the measures with non-
HDL cholesterol, type 1 diabetes patients were more
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Fig. 2 Funnel plots-control of lipids. Funnel plots of the centre specific scores for the threshold measure and the clinical action measure for the
control of lipids. Each circle represents a centre. Centres were given a random identifier. Only centres with five or more diabetes patients were
included. The red line represents the overall mean proportion of patients meeting the measure. Centres with a score more than two standard
deviations from the overall mean proportion (black dashed line) are marked in blue and centres with a score more than three standard deviations
from the overall mean proportion (black solid line) are marked in red
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Fig. 3 Funnel plots-control of blood pressure. Funnel plots of the centre specific scores for the threshold measure and the clinical action measure
for the control of blood pressure. Each circle represents a centre. Centres were given an anonymous rank number. Only centres with five or more
diabetes patients were included. The red line represents the overall mean proportion of patients meeting the measure. Centres with a score more
than two standard deviations from the overall mean proportion (black dashed line) are marked in blue, centres with a score more than three
standard deviations from the overall mean proportion (black solid line) are marked in red
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Table 4 Patient characteristics associated with meeting the TM and the CAM
Diabetes type T1 T2
Meeting the measure TM–CAM− TM–CAM + TM + CAM + TM–CAM− TM-CAM + TM + CAM +
A. LDL cholesterol
n 196 30 342 347 62 696
Age (years), mean 48 51 51 * 69 71 69
Diabetes duration (years), mean 20 20 22 17 17 18
Time before start insulin therapy (years), mean 0.2 0.3 0.5 7.8 8.2 8.6
Duration insulin therapy (years), mean 20 20 21 9.2 8.4 9.2
Smoking status (%)
Never smoked 63.7 50.0 65.8 65.6 59.3 66.9
Ex-smoker 13.5 23.3 12.7 25.0 28.8 24.2
Smoker 22.8 26.7 21.5 9.4 11.9 8.9
Presence of complication (%)
CV_hist1 (° for T2D) 8.7 10.0 4.1 40.9 38.7 15.5
CV_hist2 (° for T1D, ° for T2D) 13.8 16.7 4.4 48.4 50.0 18.7
CV_hist3 ($ for T1D, ° for T2D) 15.4 18.5 6.2 52.4 55.2 24.2
Microvascular complication 51.6 60.9 53.8 71.7 81.8 73.2
Absent foot pulses or abnormal sensitivity 14.2 16.0 16.0 36.3 43.1 33.5
Treated with (%)
Antiplatelet drugs (* for T1D) 29.1 50.0 36.9 71.6 69.4 74.5
Lipid-lowering drugs ($ for T1D, $ for T2D) 32.6 93.3 50.9 71.5 93.5 83.5
Antihypertensive drugs 40.8 46.7 51.0 86.4 87.1 87.0
Oral antidiabetic drugs (° for T2D) 7.7 13.3 8.9 51.3 33.9 58.4
B. non-HDL cholesterol
n 315 49 870 713 125 1349
Age (years), mean 47 49 50 $ 69 70 70
Diabetes duration (years), mean 19 21 22 $ 17 17 18
Time before start insulin therapy (years), mean 0.2 0.4 0.3 7.9 7.5 8.0
Duration insulin therapy (years), mean 18 21 22 ° 8.9 8.7 9.5
Smoking status (%)
Never smoked 57.2 61.7 65.0 60.5 60.4 65.0
Ex-smoker 15.1 19.1 14.9 27.8 29.7 25.2
Smoker 27.6 19.1 20.0 11.7 9.9 9.8
Presence of complication (%)
CV_hist1 (° for T1D, ° for T2D) 9.5 8.2 4.0 37.5 40.3 17.4
CV_hist2 (° for T1D, ° for T2D) 12.4 10.2 5.3 45.7 55.2 21.1
CV_hist3 ($ for T1D, ° for T2D) 13.9 14.6 7.8 50.1 60.3 27.0
Microvascular complication (* for T2D) 52.1 73.0 53.8 74.7 85.3 73.9
Absent foot pulses or abnormal sensitivity (* for T2D) 12.0 15.4 14.8 37.0 43.3 32.4
Treated with (%)
Antiplatelet drugs ($ for T1D) 22.2 36.7 33.0 72.1 69.6 72.4
Lipid-lowering drugs (° for T1D, ° for T2D) 29.5 98.0 45.2 69.1 95.2 81.9
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likely to meet the TM or CAM than patients with type 2
diabetes (TM-CAM-: 25.5 % type 1 vs. 32.6 % type 2 dia-
betes patients, TM-CAM+: 4.0 % type 1 vs. 5.7 % type 2
diabetes patients, TM +CAM+: 70.5 % type 1 vs. 61.7 %
type 2 diabetes patients, χ2-test: p < 0.01).
In general, type 1 diabetes patients meeting the TM
and CAM were older, had a longer diabetes duration
and a slightly longer duration of insulin therapy than
those neither meeting the TM nor the CAM. These as-
sociations with age and diabetes duration were less pro-
nounced for the type 2 diabetes patients. Patients
meeting the TM and the CAM had less frequently CV
history than those neither meeting the TM nor the
CAM, and the type 1 diabetic patients meeting the TM
and the CAM were slightly more often treated.
Patients that did not meet the TM, but met the CAM
had a slightly higher prevalence of microvascular com-
plications and absence of foot pulses or abnormal sensi-
tivity than those neither meeting the TM nor the CAM,
and those meeting the TM and the CAM. They were in
general more often treated, especially with lipid-lowering
drugs.
Discussion
This study shows that scoring quality of diabetes care
within a centre based on a classical TM may be mislead-
ing, and that low-complexity data elements available
from a nationwide quality improvement initiative can be
used to construct a more fair measure of quality of care.
Our first objective was to investigate the feasibility of
constructing a CAM for the control of lipids from an
existing cross-sectional study including mostly low-
complexity data elements. Although a major barrier to
create such a more complex measure is the availability
of the additional data elements [6], we showed that all
additional data elements were present for >95 % of our
study population, making the CAM a feasible measure
of quality of care without affecting the number of pa-
tients on which quality of care is calculated. As the
CAM requires longitudinal data, we combined two con-
secutive data collections, which allowed us to create a
study population of which quality of care could be evalu-
ated over time. We did not have information on the
writing of prescriptions or refills, or on drug dosages. As
a result, we were not able to give credit to patients that
were already on maximum treatment dose, or had inten-
sified their treatment by increasing the dose without
adding a new class of drugs. However, information on
drug dosages is a high-complexity data element, and in
practice, few care providers are able to provide these
data without a high additional burden. Currently, efforts
promoting the use of electronic medical records contain-
ing extractable data fields and comprehensive automated
data sources will decrease this burden. In turn, the
CAM can be fine-tuned further for provider’s actions
upon poor outcome.
Our second aim was to investigate how quality of care
defined by the CAM related to that defined by the TM.
In general, the use of the CAM will always lead to equal
or higher scores of quality of care. Whereas the TM only
gives credit to patients with an LDL (or non-HDL) chol-
esterol value below target, the CAM will in addition give
credit to patients with an LDL (or non-HDL) cholesterol
value above target when lipid-lowering treatment was
initiated or intensified while respecting possible contra-
indications for treatment. We used end-stage kidney
failure (transplantation, peritoneal dialysis or haemodi-
alysis) as a possible contraindication, although the use-
fulness of statins in end-stage kidney failure is still
debated in the literature [17]. Our results confirmed a
systematic and significant increase in the score of quality
of care based on CAM compared to TM. This increase
was more pronounced when the target value was lower.
Meeting the measure of good care was associated with
a number of patient characteristics. In general, patients
meeting the TM (and consequently the CAM) were
more often patients without CV history. Within the
population of patients not meeting the TM, those meet-
ing the CAM had a slightly higher prevalence of micro-
vascular and foot complications compared to those not
meeting the CAM. As treatment is a component of the
CAM, they were more often treated, especially with
lipid-lowering drugs.
We also found a general positive evolution in the pro-
portion of patients treated during the measurement
period. Some of these patients that started treatment will
meet the TM as they had, at the time of the index value,
an LDL (or non-HDL) cholesterol value below target.
Table 4 Patient characteristics associated with meeting the TM and the CAM (Continued)
Antihypertensive drugs ($ for T1D) 35.9 44.9 45.8 84.9 83.9 86.2
Oral antidiabetic drugs ($ for T2D) 8.0 8.2 8.4 53.7 41.9 56.4
Patient characteristics that were associated with meeting the TM and the CAM based on LDL cholesterol (Table 4a) and non-HDL cholesterol (Table 4b). Mean age,
diabetes duration, time before start insulin therapy and duration of insulin therapy is compared between the population neither meeting the TM nor the CAM
(TM-CAM-), those not meeting the TM but meeting the CAM (TM-CAM+) and those meeting the TM and the CAM (TM + CAM+). Statistical significance between
means was tested with the Pairwise Wilcox test, Holm adjustment: p < 0.001(°), p < 0.01 ($) and p < 0.05 (*) vs. not meeting the TM or the CAM (TM-CAM-). The proportion
of patients with a complication, treated with drugs, and the distribution of smoking status is compared between the population neither meeting the TM nor the CAM
(TM-CAM-), those not meeting the TM but meeting the CAM (TM-CAM+) and those meeting the TM and the CAM (TM + CAM+). Statistical significance between
percentages was tested with the χ2-test: p < 0.001 (°), p < 0.01 ($) and p < 0.05 (*)
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Nevertheless, our study showed that 30–40 % of these
patients still remained to be picked up by the CAM,
strengthening the use of the CAM over the TM. Indeed,
there is a move away from one–time point, one-target-
for-all, measures towards measures based on control of
risk factors that take into account patient characteristics
and the longitudinal nature of chronic care [2, 6, 10].
The classical TM only gives credit to a good intermedi-
ate outcome, favouring centres with less severe patients
or patients that respond well to therapy. Poor outcome
could reflect inadequate attention from physicians, but
also individual patient factors [18]. In addition, one can
speculate that if the quality score is used for public ac-
countability or reimbursement, the temptation to de-
select patients that are more difficult to control might
exist. A more fair way of assessing quality of care also
gives credit to an appropriate action upon a poor inter-
mediate outcome.
Finally, we wanted to compare the reliability of pro-
vider profiling using the CAM and the TM. Using the
CAM still leaves sufficient variance between centre-
specific scores and room for further improvement,
allowing it to be useful for benchmarking. The funnel
plots showed that centres identified as performing bet-
ter (or worse) than the others based on the TM were
not by definition those that performed better (or worse)
based on the CAM. This indicates that quality of care
defined by the classical TM was overestimated (or
underestimated). Original high outliers moving into the
normal range were centres whose scores were overesti-
mated using the TM. Indeed, for these centres, the
CAM-induced increase in the centre-specific score was
lower than the CAM-induced increase in the overall
score. In other words, they lost relatively more points
using the CAM compared to the other centres. The op-
posite is true for the original low outliers moving to the
normal range, and for the centres moving from the
normal range to the high-outlier range. These were
centres whose scores were underestimated using the
TM. For these centres, the CAM-induced increase in
the centre-specific score was higher than the CAM-
induced increase in the overall score. They gained rela-
tively more points using the CAM compared to the
other centres.
The principle of scoring quality of care based on a
CAM is general and can be applied to the control of
other intermediate outcomes [7, 19, 20]. Indeed, we ap-
plied the principle to the control of blood pressure.
Similarly as for the control of lipids, the position related
to the other centres changed for 13 % of the centres, in-
dicating that judging quality of care based on a TM
might be misleading.
The approach of our study makes it difficult to com-
pare with other studies that created a CAM for the
control of lipids in diabetes patients [7, 21, 22]. Whereas
the other studies investigated the clinical action within a
certain timeframe after a high-index LDL value, we stud-
ied the clinical actions taken before or at the moment of
the high-index LDL value. IQED is a quality improve-
ment initiative that investigates the care given to pa-
tients in the past year by asking the physicians to
register the patient’s most recent values. Based on those
values, centres are scored and ranked. We believe that
credit should be given when a patient’s therapy has been
initiated (or intensified) although the patient did not
meet the target value (yet). Furthermore, we adjusted
our target values according to CV history, moving away
from the one-target-for-all measures.
In addition to the limitations already mentioned, our
study has one additional limitation. Our measurement
period was constructed by the combination of two con-
secutive cross-sectional data collections, and exceeded
the 120 days mentioned by Sidorenkov et al. as the
period in which clinical actions should be taken [10] and
those used in other studies [7, 21, 22]. As a result, we
might have missed intermediate test results and therapy
changes. However, the diabetes stage in our study popu-
lation was advanced: type 1 and type 2 diabetes patients
on at least two insulin injections a day, and a high preva-
lence of micro- and macrovascular complications. One
can speculate that our study population was less exposed
to drastic changes in therapy and subsequent outcomes,
and, in the context of more stable chronic care delivery,
a longer measurement period may actually better fit our
needs. In addition, our results showed that still 30 to
40 % of the patients that started therapy during the
measurement period did not meet their target value, and
consequently were reclassified from receiving subopti-
mal to good care using the CAM.
Nevertheless, as mentioned earlier, efforts should be
made to further develop structured electronic medical
records. The availability of extractable data fields and
more automated data collection tools will decrease the
burden to collect more high-complexity data elements
reflecting clinician’s actions (such as drug dosages and
changes in regimen), and allow to collect multiple recent
values of a measurement (e.g. LDL cholesterol) within
one data collection. The latter would provide a clearer
picture of the evolution of a patient in relation to clinical
actions.
Conclusions
In summary, we created a more fair measure of quality
of care that is immediately applicable for benchmarking
feedback in a quality improvement initiative. Further de-
velopment of the electronic health records will support
optimization of the CAM.
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